ArticleFrontiers in bioengineering and biotechnology2026
Storage-associated physicochemical changes in extracellular vesicles derived from human mesenchymal stromal cells.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) are considered a promising therapeutic tool due to their involvement in intercellular signaling and their ability to carry a wide range of biologically active molecules, including proteins, lipids, and nucleic acids. Standardized protocols for EV manufacturing and evaluation of EV properties under different storage conditions are important to ensure the quality, reproducibility, safety, and therapeutic efficacy of EV-based products. This study evaluated the physicochemical stability of EVs derived from MSCs of various tissue origins under different storage temperatures. Materials and Methods: MSC populations were isolated from adipose tissue (ADSCs), umbilical cord (UC-MSCs), and dental pulp (DPSCs). The isolated cells met the minimal criteria for defining MSCs. EVs were isolated from conditioned media by differential ultracentrifugation and characterized by nanoparticle tracking analysis (NTA) and ELISA detection of the EV-specific markers CD63, CD81, and TSG101. Total protein concentration was determined using the Pierce BCA colorimetric assay. The physicochemical stability of MSC-derived EVs diluted in Hank's solution was evaluated at predefined intervals during storage at +4 °C to +6 °C, -20 °C, and -80 °C. Results: EV particle concentration and total protein concentration remained stable for at least 14 days at +4 °C to +6 °C and for at least 6 months at -20 °C. EV samples preserved their characteristics for at least 10 months when stored at -80 °C. The assessment of bFGF complemented conventional physicochemical characterization by providing information on the preservation of a selected biologically relevant quality attribute of EV preparations. Conclusion: MSC-derived EVs diluted in saline solution retain physicochemical stability during long-term storage under clinically relevant conditions, supporting the further development of EV-based therapeutic products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.